Business Wire

Morgan Stanley Investment Management Launches ESG Strategies Across Europe Managed by Calvert Research and Management

4.5.2022 10:30:00 EEST | Business Wire | Press release

Share

Calvert Research and Management (Calvert), a subsidiary of Morgan Stanley Investment Management, today announced the European launch of a suite of responsible investing strategies focused on Environmental, Social and Governance (ESG) factors. The new Calvert strategies meet the SFDR Article 9 criteria and have a sustainable investment objective across the ESG spectrum. This news follows MSIM’s acquisition of Eaton Vance, Calvert’s parent company in March, 2021.

Calvert, a recognized pioneer and leader in responsible investing since 1982, employs proprietary fundamental research, financially material ESG data analysis and direct company engagement to deliver competitive investment results across asset classes. The newly available strategies form a robust suite of offerings that invest in companies with leading ESG characteristics with the core objective of long-term value creation and positive global impact.

The Calvert Article 9 Funds are available through Morgan Stanley Investment Management’s distribution network and include the following:

  • MSINVF Calvert Sustainable Developed Europe Equity Select Fund
  • MSINVF Calvert Sustainable Developed Markets Equity Select Fund
  • MSINVF Calvert Sustainable Emerging Markets Equity Select Fund *
  • MSINVF Calvert Sustainable US Equity Select Fund
  • MSINVF Calvert Sustainable Diversity, Equity and Inclusion Fund
  • MSINVF Calvert Sustainable Climate Aligned Fund

“We are excited about leveraging Morgan Stanley Investment Management’s leading non-U.S. distribution capabilities to bring Calvert’s proven, Principles-based sustainable investment strategies to a much broader universe of investors,” said John Streur, President and Chief Executive Officer of Calvert Research and Management. “Our proprietary research system drives our investment process and enables us to identify the companies leading their peers in managing financially material ESG risks and opportunities, and those that are positioned for longer-term success and improved societal outcomes.”

Promoting environmental sustainability and resource efficiency, advocating for equitable societies and enhanced societal outcomes as well as demanding accountable governance and transparent operations are the core of the Calvert Principles for Responsible Investment, which form the foundation of Calvert’s investment process.

Calvert is a signatory to, and has played a leading role in spearheading, a number of global initiatives such as the United Nations Environment Programme Finance Initiative’s Principles of Responsible Investing (PRI), the Women’s Empowerment Principles and the UN Global Compact. Calvert also partners extensively with leading academic institutions and other ESG-oriented organizations to promote industry leading collaborative research.

“The combination of our research and engagement processes plus our work to support global change initiatives position us to offer impact-driven, responsible investing strategies that deliver long-term shareholder value and drive positive change,” added Mr. Streur.

“We are delighted to be able to bring Calvert’s historic understanding of ESG analysis, knowledge of responsible investing and success in long-term value creation to our European clients,” said Jacques Chappuis, Global Head of Distribution and Co-Head of the Solutions and Multi-Asset Group at Morgan Stanley Investment Management.. “Investors are increasingly focused on sustainability, and the launch of these new funds demonstrates our focus on delivering our clients best-in-class and market-leading products and solutions that align investor values with financial outcomes. European investors have a sophisticated understanding of how sustainability factors can lead to business success and Calvert has been honing this process for 40 years.”

* This fund is approved and will be available in the coming weeks

About Calvert Research and Management

Calvert Research and Management is a global leader in responsible investing. Calvert sponsors one of the largest and most diversified families of responsibly invested mutual funds, encompassing active and passively managed equity, income, alternative and multi-asset strategies, with approximately $37.3 billion in assets under management as of March 31, 2022.

With roots in responsible investing dating back to the 1982 launch of the first mutual fund to oppose investing in companies doing business in apartheid-era South Africa, the firm seeks to generate favourable investment returns for clients by allocating capital consistent with environmental, social and governance best practices and through structured engagement with portfolio companies. Headquartered in Washington, D.C., Calvert manages assets on behalf of funds, individual and institutional separate account clients, and their advisors. Calvert Research and Management is a wholly owned subsidiary of Morgan Stanley Investment Management.

About Morgan Stanley Investment Management

Morgan Stanley Investment Management, together with its investment advisory affiliates, has more than 767 investment professionals around the world and $1.4 trillion in assets under management or supervision as of March 31, 2022. Morgan Stanley Investment Management strives to provide outstanding long-term investment performance, service and a comprehensive suite of investment management solutions to a diverse client base, which includes governments, institutions, corporations and individuals worldwide. For further information about Morgan Stanley Investment Management, please visit www.morganstanley.com/im.

About Morgan Stanley

Morgan Stanley (NYSE: MS) is a leading global financial services firm providing a wide range of investment banking, securities, wealth management and investment management services. With offices in 41 countries, the Firm's employees serve clients worldwide including corporations, governments, institutions and individuals. For more information about Morgan Stanley, please visit www.morganstanley.com.

Disclaimer:

FMIL

This marketing communication has been issued by Morgan Stanley Investment Management Fund Management (Ireland) Limited. Morgan Stanley Investment Management Fund Management (Ireland) Limited is regulated by the Central Bank of Ireland. Morgan Stanley Investment Management Fund Management (Ireland) Limited is incorporated in Ireland as a private company limited by shares with company registration number 616661 and has its registered address at The Observatory, 7-11 Sir John Rogerson's Quay, Dublin 2, D02 VC42, Ireland.

MSINVF CBDF

This is a marketing communication. Applications for shares in the Fund should not be made without first consulting the current Prospectus and the Key Investor Information Document (“KIID”), which are available in English and in the official language of your local jurisdiction at morganstanleyinvestmentfunds.com or free of charge from the Registered Office of Morgan Stanley Investment Funds, European Bank and Business Centre, 6B route de Trèves, L-2633 Senningerberg, R.C.S. Luxemburg B 29 192. A summary of investor rights is available in English at the same website.

If the management company of the relevant Fund decides to terminate its arrangement for marketing that Fund in any EEA country where it is registered for sale, it will do so in accordance with the relevant UCITS rules.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Relations:
Tom Walton
Tom.Walton@morganstanley.com

Colleen McElhinney
Colleen.McElhinney@morganstanley.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 08:00:00 EEST | Press release

Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufacturing site. All other aspects of the BLA, including safety- and efficacy-related parts, did not solicit deficiencies to be addressed. The FDA made observations during the PLI for which Galderma is putting in place corrective and preventive actions. Galderma will also be seeking further guidance through continued open dialogue with the FDA toward resolution of the relevant observations. Galderma plans to rapidly respond to the CRL and advancing RelabotulinumtoxinA in the U.S. remains a top priority. The ob

EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 04:45:00 EEST | Press release

EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia

Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release

Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release

Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye